BenevolentAI Awarded Technology Pioneer Status by World Economic Forum

Every year, the World Economic Forum welcomes leading early-stage technology companies from around the world into its Technology Pioneer’s community. In its own words, these companies are “poised to have a significant impact on business and society”. Today we are delighted and humbled to be named as one such Technology Pioneer.

Read More
BenevolentAI raises $115 million to extend its leading global position in the field of AI enabled drug development

BenevolentAI raises $115 million, now valued at $2 billion. Funds raised to significantly scale BenevolentAI drug development activities, broaden the disease areas on which it focuses, and extend its AI platform capabilities

Read More
BenevolentAI acquires advanced Cambridge research facility to accelerate its AI-enabled drug development

BenevolentAI acquires clinical development research facility in Cambridge to drive AI drug discovery. Acquisition creates first AI company capable of covering entire drug development process from drug discovery to clinical development.

Read More
BenevolentAI hires Head of GSK Discovery Performance Unit as VP Drug discovery

Ian Churcher joins BenevolentAI as its new VP of Drug Discovery & Preclinical Development He joins BenevolentAI from GSK where he headed a Discovery Performance Unit focussed on progressing new approaches to drug discovery including pioneering development of Protein Degradation technology.

Read More
BenevolentAI hires new head of cheminformatics from the Institute of Cancer Research

Dr Nathan Brown joins BenevolentAI as new Head of Cheminformatics. He has extensive experience as a software designer and has developed many novel algorithms to maximise the impact of the experimental data generated in medicinal chemistry and cancer biology.


Read More
Exclusive license agreement with Janssen for clinical stage drug candidates

BenevolentAI has signed an exclusive license for a series of novel clinical stage drug candidates with Janssen Pharmaceutica NV (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The agreement was facilitated by the Johnson & Johnson Innovation Centre in London.

Read More
BenevolentAI, the pioneering London-based company using artificial intelligence to advance pharmaceutical development, appoints head of BBSRC as new Chief Executive

Jackie Hunter PhD CBE FBPharmacolS FMedSci, currently the Chief Executive of the Biotechnology and Biological Sciences Research Council (BBSRC), announced today that she will leave the BBSRC to become CEO of BenevolentBio, a business unit of BenevolentAI, a pioneering London-based technology company that applies artificial intelligence to transform the process of drug discovery in the pharmaceutical industry. 

Read More